Precision medicine is here, with rapid advancements in the technologies, tools, and life-saving products entering the market for the treatment of serious and life-threatening disease. In May 2017, the United States Food and Drug Administration (FDA) approved the first cancer treatment for solid tumors based on a genetic biomarker rather than the tissue of origin.
1 One month later, the agency approved a companion diagnostic panel that uses next generation sequencing (NGS) to simultaneously screen a genetic sample for 23 cancer genes, three of which have FDA-approved therapies for non-small cell lung cancer. ated in April 2015, which targeted cell biologists, tissue engineers, and regenerative medicine physicians." The company used social media to announce the project and ultimately share its histone variant H2A biomarker, called H2A.Z asymmetry, with qualified respondents. 1 2 In exchange, respondents agreed to test the new biomarker tool to identify and count stem cells and report back with findings and data points. 13 The goal was to generate the information quicker and cheaper, possibly with an eye on eventual approval and marketing of the technology.
1 1 At the very least, the initiative contributed to the company's patentprotected intellectual property portfolio relating to the H2A biomarker.
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Industry is not the only source of crowdsourcing for genomic inquiry and exploration. Academic medical institutions, research consortia, patient advocacy groups, and others are creating crowdsourcing platforms based on tools to detect, collect, and evaluate genetic and genomic information.
1 6 Regulators are even getting into the NGS game-the FDA launched the online portal precisionFDA in December 2015, providing "a community platform for NGS assay evaluation and regulatory science exploration."" Deciphering information generated and published on this crowdsourced, cloud-based site may be integral to biomarker identification, industry standard setting, clinical trial development, and, ultimately, regulatory assessment and adaptability.
The growth of NGS crowdsourcing models necessarily means widespread collaborations of academic medical centers, researchers, patients and patient advocates, private foundations, medical product innovators, and regulators. Not all of which subscribe to the same norms and expectations in the sharing economy. Emerging questions surrounding the expansion of players facilitated by NGS crowdsourcing involve identification and management of complex conflicts of interest, proper incentive structures, access to and sharing of research samples and health information, inventorship status and patent rights, payments and contractual agreements, licensing terms, and eventual profit share. This article contributes to the conversation by exploring the precisionFDA online crowdsourcing platform in terms of use, functionality, and legal disclaimers and terms. It then offers several modest reflections on the legal and regulatory implications that may arise as crowdsourcing models are integrated into research and development.
I. BRIEF HISTORY OF CROWDSOURCING

A. Early Uses and Current Scope
The concept of pooling information and resources to solve a problem is not a groundbreaking one. Scholars routinely reference the origin of the concept as 1714, the year the British government established a prize as a mechanism to gather solutions from the broad population for determining accurate longitude at sea.
1 " The term crowdsourcing itself, however, was introduced into the lexicon in 2006.19 Wired Magazine author Jeff Howe described crowdsourcing in a blog post as "the act of taking a job traditionally performed by a designated agent (usually an employee) and outsourcing it to an undefined, generally large group of people in the form of an open call." 20 The literature identifies four general categories of crowdsourcing: crowd creation (e.g., the 1714 Longitude Prize), crowd voting, crowd funding, and crowd wisdom. 21 The latter, crowd wisdom, is of relevance to the topic of crowdsourcing genomics, where the diverse knowledge base of a group is targeted to contemplate research questions.
22
Crowd wisdom forms of crowdsourcing operate on an open source model, providing materials to users, posing a particular challenge, and aggregating the responses on a publicly available platform. 23 The open source software programs Apache and Linux are prime examples-they "involve the contribution of dispersed individuals working asynchronously to build and refine a unified product." 24 Other examples from the recent literature include crowdsourcing of digital images to populate the stock photo market, 25 crowdsourcing through municipal discussion boards to collect information about water and sewer rate hikes, 26 and crowdsourcing for new television commercial ideas. 27 With the explosion of social media outlets, crowdsourcing has become commonplace.
Many have reflected on the advantages and disadvantages of general crowdsourcing models and this article will not attempt to exhaust or recreate the literature on this point.28 On the advantage side, crowdsourcing targets a large and diverse population of people, is typically not geographically limited, the rate of response is rapid and possibly ongoing, and it is less expensive than employing individuals to perform the tasks. It also energizes a community around a single goal and has the potential to generate goodwill and notoriety for the company or individual who initiated the crowdsourcing campaign. However, those responding may not necessarily be adequately qualified, there may be overwhelming rates of responses with varying utility, and there are numerous legal and ethical questions that arise, as described in Part III.
B. Crowdsourcing Medicine and Clinical Trials
In the last five years, crowdsourcing models have moved into medicine and clinical trials. Recent scholarship terms crowdsourcing organized by research scientists as "challenges," which are competitions seeking voluntary labor from the scientific community to solve targeted problems. 37 Challenges have been initiated by forprofit companies, health providers, disease foundations, and academics and are broadcast to a broad community.
38 Notable challenges in the life sciences include those in the realm of structural biology, genomics, systems biology, medicine, and data assessment and analytical tools.
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One concerted area of crowdsourcing that is experiencing rapid attention is that of NGS and biomarker development to inform cancer drug innovations. The 21st Century Cures Act defines a biomarker as "a characteristic (such as a physiologic, pathologic, or anatomic characteristic or measurement) that is objectively measured and evaluated as an indicator of normal biologic processes, pathologic processes, or biological responses to a therapeutic intervention.""o Biomarkers can be categorized based on their purpose. Predisposition biomarkers assess an individual's risk of developing a particular disease; diagnostic biomarkers identify a specific disease; prognostic biomarkers serve to predict the course of disease in an individual; monitoring biomarkers monitor the progression of disease; and predictive biomarkers predict the response or reaction to a drug." The 21st Century Cures Act also prioritizes cancer research and drug development. It appropriates $4.8 billion in funding to the National Institute of Health for the Precision Medicine Initiative and Cancer Moonshot 2020 over the next decade.
4 2 The hope is that discoveries fueled by NGS capabilities will identify genetic biomarkers critical for cancer screening and appropriate treatment based on an individual genetic profile.
There are very recent successes arising out of NGS and biomarker identification for cancer. As noted earlier, the FDA approved Merck's Keytruda (pembrolizumab) in May 2017 for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors. 43 Patients who will respond favorably to Keytruda possess the microsatellite instability-high (MSI-H) or mismatch repair deficient (dMVIR) biomarker. Likewise, NGS technology has enabled the development of medical devices to screen genetic samples for dozens of cancer mutations simultaneously, some of which have a corresponding approved drug." These successful drug and medical device products currently on the market were evaluated and approved by the FDA, signaling the acceptance of NGS technology and of biomarkers as clinically meaningful measures of drug efficacy. The next Part explores the FDA's efforts to inform and guide NGS and biomarker development through the precisionFDA portal.
II. THE PRECISION FDA CROWDSOURCING PLATFORM
The introduction of the FDA's crowdsourcing platform, precisionFDA, coincided with President Obama's Precision Medicine Initiative, which aimed "to accelerate biomedical discoveries and provide clinicians with new tools, knowledge, and therapies to select which treatments will work best for which patients."4 First announced in 2015, the Precision Medicine Initiative was subsequently expanded and infused with funding in the 21st Century Cures Act of 2016." Efforts to construct an online community that allowed users to "test, pilot, and validate existing and new bioinformatics approaches for [the] 
A. Use and Functionality
The developer of the precisionFDA platform, DNAnexus, envisions users to be NGS-test providers, pharmaceutical and biotech companies, standard-setting institutions, health-care providers, academic medical centers, patient advocacy groups, and various research consortia. 53 Users must register to acquire full access to precisionFDA; visitors may also choose to acquire temporary access, allowing them to browse the site for 30 days. Users who request temporary access receive the following statement in an email along with a personal link:
Note: PrecisionFDA is a beta regulatory research sandbox and is intended to inform a broad community. As you browse precisionFDA, you may become interested in obtaining a precisionFDA user account, in order to be able to actively contribute. In that case, please contact PrecisionFDAafda.hhs.gov with your plan. Community members who have committed to providing information and programs that can be useful in our initial focus of NGS Clinical Test Development and Validation will be assessed for contributor level access.
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Upon basic access, the site provides options for users to access documentation and tutorials explaining the resources available and the scope of content. The top panel of the website displays icons denoting the different categories of resources. Those with temporary access may browse the site but cannot access all of the content.
Once users acquire an account, they are able to upload data and programming files to cloud storage. 55 Uploaded files can be used anywhere within precisionFDA (e.g., "downloaded, published, or provided as input" within applications).
56 There are both public (i.e., published) settings and private settings available on the website. 51 Users can access public files or attach their own files; furthermore, after clicking on a specific public file, users can also view notes, discussion threads, and comparisons run by users.
58 A key feature of precisionFDA is the ability of users to compare two data sets (in the variant call format) that evaluate NGS assays. 59 The comparisons are run with a test set and a benchmark set and users specify what genomic region to compare.
60 Several metrics are reported at the conclusion of a comparison including true and false Users can also access, manage, and share software applications by publishing them.
DNAnexus to
6 4 Again, public and private settings ensure that users can either develop their applications for their own use, or share publicly via the website. The default application setting dictates that applications cannot access the internet of the users, which "increases user comfort and lowers the barriers for users to try out apps." 6 6 There is also a tracking feature within the website that that depicts all public revisions to an application.67 Users can also choose to share software assets, which are described on the site as "building blocks" to application development. 68 Users have already been challenged by the FDA to test the accuracy and reproducibility of software applied to genetic research through the online portal and to identify genetic variants within select datasets. 69 PrecisionFDA has posed four focused challenges to users: the Consistency Challenge that ran from February 2016 through April 2016, the Truth Challenge that ran from April 2016 to May 2016, the App-a-thon in a Box Challenge that ran from August 2016 to December 2016, and the Hidden Treasures-Warm Up Challenge that ran from July 2017 to September 2017.70 Challenges are designed to advance quality standards to achieve accurate and consistent results in the context of genetic tests.
7 ' The results are published, and a winner is selected based on comparison 64. FDA, Apps, PRECISIONFDA, https://precision.fda.gov/docs/apps [https://perma.cc/SZ8U-82GK] ("Apps are, in essence, shell scripts that run inside a Linuxvirtual machine on the cloud, and which are designed to perform whatever specific task has been envisioned by the app author. Apps come with an 1/0 specification, a 'contract' that describes the kinds of inputs they receive and the kinds of outputs they are expected to generate. The connection between the current use and functionality of precisionFDA and the regulatory process is as yet unclear. The FDA has published several draft guidance documents" and discussion papers" on analytical and clinical strategies to support the development of NGS diagnostic tests. FDA's Chief Health Informatics Officer describes precisionFDA "as a community rather than [as] a way to regulate." 7 6 As of July 2016, the website included 1,400 users from 600 organizations," though it is not evident how users are contributing to the platform or whether specific products have been developed using the public information. Stated long-term goals for precisionFDA include standard development and best practices for NGS bioinformatics.
B. Legal Disclaimers and Terms
Use of the website is not without limitations and legal specifications. Before a user logs into the website, the following disclaimer appears at the bottom of the page:
By logging into precisionFDA, you are accessing a U.S. Government information system. Usage of precisionFDA may be monitored, recorded, and subject to audit. Your use of precisionFDA indicates your consent to monitoring and recording of precisionFDA usage, and if such monitoring reveals possible criminal activity, precisionFDA personnel may provide such monitoring as evidence to law enforcement officials. Any unauthorized use of the system is prohibited and subject to criminal and civil penalties.
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The precisionFDA website also contains both the Terms of Service and a link to the FDA website housing both the Privacy Policy and Disclosure Policy. 8 3 Users are not allowed to grant third party access to anything within precisionFDA nor sell, rent, transfer or make anything from precisionFDA available to third parties." Users also agree not to add third party information to the site without appropriate approval, nor will they add Protected Health Information (PHI) and Personally Identifiable Information (PII) without all necessary permissions and informed consents. The FDA agrees that they shall not access any information that is contained solely in a private space and that they will maintain the security of the site consistent with industry standards. The short intellectual property (IP) portion of the agreement states that there are no IP rights either implied or otherwise granted to either party; however, it does provide that the user "grants FDA a nonexclusive, nontransferable, revocable, royalty-free, limited license . . . to access and use . . . IP solely for . . . delivering [s]ervices."" The user data section of the agreement also instructs that users are not to store confidential commercial information in a way that makes it "accessible to all [u]sers";" nor are users to "store [t]rade [s]ecrets on PrecisionFDA." 8 9 Notably absent is any express requirement in the terms of service that a user attribute precisionFDA in publications or place those publications in the public domain.
The FDA's online privacy policy explains that the FDA collects two types of information: information voluntarily entered and information automatically collected.
9 0 The automatically collected information includes a user's computer IP address, the user domain from which the website was accessed, the website that redirected the user to precisionFDA or other FDA websites, the date and time the user accessed the site, the length of time the user remained on the site, the name and version of the user's computer operating system, and the pages visited. 91 The website disclosure policy further provides that the "FDA will not disclose, give, sell, or transfer any personally identifiable information (PII) 93 License agreements may cover topics such as usage restrictions, waiver of liability, insurance indemnification, publication embargoes, assignment, and ownership of intellectual property. 94 The FDA assures that all user licenses are published and publicly available in connection with the public files; therefore, any user who accepts the licensing terms and opens the file is subject to those licensing terms. 95 Users must agree to those terms by clicking the "accept license" button at the top right of the page to access the files. 96 However, it appears that the user need not even open the license to accept the terms. After an item has been published with the license, users can manage and view who has accepted the license and subsequently block individual users. 97 The website has a model license agreement posted in the tutorial section of the materials within the licensing description. Overall, precisionFDA users are thus subject to several layers of legal documents originating from the FDA: the general disclaimer, the Terms of Service, the Privacy Policy, and the Disclosure Policy. Users may also be subject to individual licensing agreements for use of particular applications or files, which are developed by outside parties.
III. LEGAL AND REGULATORY IMPLICATIONS
Scholars have just begun to assess the vast range of legal issues associated with crowdsourcing models as a general matter. These legal issues span various traditionally recognized areas, including contract law, securities law, insurance law, data privacy and confidentiality, employment law, IP law, and potentially gaming law.
99 When looking to the use of NGS crowdsourcing in medicine and life sciences, the pressing legal questions chiefly revolve around the IP status of the information shared and collected, as well as the regulatory implications, given the lucrative potential of discoveries and innovations in the life sciences. The new platform developed for the FDA is in early rollout phases and uncertainty exists about its long-term purposes. As noted earlier, the website is limited in functionality and accessible in full format only after individuals secure a username and password.100 Although the FDA has issued several user challenges and has provided tools and app-sharing mechanisms, it is unclear how the FDA will continue to support the platform, or how the agency may begin to integrate crowdsourced information into their contemplation of appropriate regulation and standard setting. Reflecting on the attributes of the precisionFDA platform coupled with the legal provisions described in Part II, this Part offers several modest insights on the relationship to regulatory review and approval, as well as possible IP implications. First, at the regulatory level, the FDA will need to determine how to integrate crowdsourced information into the regulatory process, if at all. The FDA is approving drugs, assessing NGS-based tests, and reviewing biomarker discoveries resulting from prevision medicine initiatives. Guidance from the agency acknowledges that standard-setting efforts will rely largely on information and data collected from drug and device sponsors.101 Recent legislation also presses the agency to take into consideration "real world evidence" and "patient experience data" when reviewing new drug applications. 102 It is unclear what threshold of reproducibility, validity, and reliability will be necessary to achieve standard-status for a particular biomarker or when information gathered and shared on the FDA-sponsored site may be relevant to regulatory review for a given product.
The FDA also needs to consider foreseeable issues with regard to the validity and reliability of the public information available through the online platform, and how information shared through the platform is maintained. Will, or should, the FDA have a role as gatekeeper and monitor? While many may advocate that the online community is well suited to regulate its behavior, this may not be true. Although the users are typically generalized as researchers and scientists-regardless of private or public affiliation-different disciplines inevitably hold varying viewpoints and norms on aspects of attribution, sharing, and collaboration. There may be opportunities for data trolls to break down the synergistic crowdsourcing community using the shared platform. There may also be concerns about protection of the information submitted and maintained on the online platform, potentially with sensitive privacy issues relating to de-and re-identification of shared data.
Second, users contributing to the website and participating in the challenges imposed by the FDA should consider the implications of these activities on ownership and access rights. While the FDA supplies privacy, security, and disclosure policies for users, individual contributors are able to publish licensing agreements and other terms relating to access to their materials. As use and traffic on the website increases, relationships will be created through contract law as users agree to select terms for use of information. It is likely that litigation will soon arise pitting precisionFDA users against each other. For example, a scenario may arise in which a license agreement will be challenged once a tangible product, whether a drug based on a biomarker identified through crowdsourcing efforts or an NGS-based test, is in existence and someone is seeking a patent or FDA approval and exclusivities. Depending on the product, different elements of the platform materials and activities will be relevant, including software aspects developed as an application, identification and analysis linked to a particular biomarker, or a detection device itself integrating software and biomarker attributes. A court will need to interpret the licensing agreement and the relationships involved under contract law principles. Much of this assessment will scrutinize the ownership and IP provisions, and terms of use.
Third, tied to questions of ownership and access framed in contract and licensing terms, are IP issues. In particular, what contributions will be recognized by patent law? In the United States, a patent is awarded for inventions that are novel, useful, nonobvious, and are adequately enabled by the written description contained within the patent application.103 The Leahy-Smith America Invents Act introduced a first-to-file system in the United States, where the first inventor to file an application achieves inventor status as long as the other subjective patent law requirements are met.10 There are also questions of joint inventorship raised by NGS crowdsourcing. 10 The federal patent law recognizes that individuals working in different locales, at different times, and in different proportions relative to the whole of the invention may be joint inventors.106 All inventors must be named on the patent application, and once granted a patent can be invalidated for failure to name a coinventor.
1 07 Much litigation has focused on teasing out who is a proper inventor.
Crowdsourcing may force a wholesale restructuring of traditional intellectual property frameworks in biomedical research. With numerous actors working on a scientific challenge, several incremental "inventions" may result in a patent-worthy outcome across a national or international network. The U.S. Patent & Trademark Office should begin to examine these issues and proactively develop an approach to joint inventorship or proportional inventorship rights.
Online communities also continue to share resources online, establishing open source databases and networks of tools for scientists. Such open source platforms are a direct response to monopolistic patent rights, which reserve the rights to use and sell in the patent holder alone for a limited time. Open source efforts such as the BioBricks Foundation-in the realm of synthetic biologyprovide an innovative example of a biology commons to avoid the stifling effect of patent rights. 10 s As research moves in the direction of open source, the intellectual property protections change. Many question whether there is a role for non-patent incentives in the life sciences and biomedical research, which will prove to be part of an ongoing debate.
The FDA has provided the life science research and scientific community with an invaluable resource through the precisionFDA platform. Launched in December 2015, precisionFDA allows private and public actors to contribute towards solving complex scientific problems arising out of NGS and genomic research. The agency is also exploring additional crowdsourcing mechanisms to inform NGS exploration and product development. As NGS crowdsourcing continues, legal and ethical questions will undoubtedly emerge in the life science industry. Many of these questions will involve the application of IP law principles and regulatory review by the FDA. This article has explored the FDA's recently launched crowdsourcing platform, precisionFDA, and offers initial modest thoughts on some of the regulatory implications.
